Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429 is registered in ClinicalTrials.gov with SyneuRx International (Taiwan) Corp as lead sponsor.

NCT NCT03094429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Lead sponsor
SyneuRx International (Taiwan) Corp
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 29, 2017
Completion date
December 31, 2026
Enrollment
287 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory schizophrenia